{
    "2021-09-27": [
        [
            {
                "time": "",
                "original_text": "医药生物行业周报：政策鼓励医疗器械国产替代 国产器械前景广阔",
                "features": {
                    "keywords": [
                        "医疗器械",
                        "国产替代",
                        "政策鼓励",
                        "前景广阔"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "药明康德(603259.SH)：子公司拟认缴1500万美元的投资基金份额",
                "features": {
                    "keywords": [
                        "药明康德",
                        "子公司",
                        "投资基金",
                        "认缴",
                        "1500万美元"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "药明康德：1500万美元认购私募基金份额",
                "features": {
                    "keywords": [
                        "药明康德",
                        "私募基金",
                        "认购",
                        "1500万美元"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业周报：确认政策底 行业迎来布局良机",
                "features": {
                    "keywords": [
                        "医药生物",
                        "政策底",
                        "布局良机"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业跨市场周报：新冠呈常态化趋势 看好新冠小分子药CDMO供应商",
                "features": {
                    "keywords": [
                        "医药生物",
                        "新冠常态化",
                        "小分子药",
                        "CDMO供应商"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业周报：从景气度、竞争力、外需逻辑看诺禾致源投资价值",
                "features": {
                    "keywords": [
                        "医药生物",
                        "景气度",
                        "竞争力",
                        "外需逻辑",
                        "诺禾致源"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物：海外新冠治疗药物Q4有望获批",
                "features": {
                    "keywords": [
                        "医药生物",
                        "新冠治疗药物",
                        "海外",
                        "Q4获批"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}